Tag Archives: retinoic acid-related (RAR) orphan receptor

Lycera’s ROR-gamma agonists for cancer immunotherapy

Celgene and Lycera entered into a $105MM collaboration on its RORϒ agonists for the treatment of cancer, as well as LYC-30937, an oral gut-directed ATPase modulator now in early-stage clinical studies. LYC-30937 is designed to treat IBD without global immune suppression. Continue reading